Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Receivables - Other: 2016-2024

Historic Receivables - Other for Akebia Therapeutics (AKBA) over the last 9 years, with Dec 2024 value amounting to $2.0 million.

  • Akebia Therapeutics' Receivables - Other rose 67.67% to $3.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.1 million, marking a year-over-year increase of 67.67%. This contributed to the annual value of $2.0 million for FY2024, which is 39.69% down from last year.
  • Per Akebia Therapeutics' latest filing, its Receivables - Other stood at $2.0 million for FY2024, which was down 39.69% from $3.3 million recorded in FY2023.
  • Akebia Therapeutics' Receivables - Other's 5-year high stood at $19.1 million during FY2021, with a 5-year trough of $1.9 million in FY2022.
  • Over the past 3 years, Akebia Therapeutics' median Receivables - Other value was $2.0 million (recorded in 2024), while the average stood at $2.4 million.
  • As far as peak fluctuations go, Akebia Therapeutics' Receivables - Other surged by 527.06% in 2021, and later tumbled by 90.04% in 2022.
  • Over the past 5 years, Akebia Therapeutics' Receivables - Other (Yearly) stood at $3.0 million in 2020, then skyrocketed by 527.06% to $19.1 million in 2021, then tumbled by 90.04% to $1.9 million in 2022, then soared by 75.33% to $3.3 million in 2023, then tumbled by 39.69% to $2.0 million in 2024.